Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
d-ala2-glp-1-plga-cooh
- Development stage
- Preclinical
- Lead developer
- Ulster University
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
D-ala2-glp-1-plga-cooh is an experimental oral drug delivery formulation consisting of a modified glucagon-like peptide-1 (GLP-1) analog encapsulated within or conjugated to poly(lactic-co-glycolic acid) (PLGA) polymers with terminal carboxylic acid groups. The peptide component, [D-Ala2]GLP-1, features a substitution of L-alanine with D-alanine at the second position, which renders it resistant to degradation by the enzyme dipeptidyl peptidase IV (DPP-IV), thereby extending its biological half-life. The PLGA-COOH matrix serves as a biodegradable carrier designed to protect the peptide from proteolytic degradation in the gastrointestinal tract and provide sustained release. Preclinical studies in diabetic db/db mice have demonstrated that oral administration of this microsphere formulation can normalize basal glycemia and enhance bioactivity during glucose challenges.
- Other names
- D-Ala2-GLP-1 PLGA microspheresD-Ala-2-GLP-1 PLGA microspheresD-Ala 2-GLP-1 PLGA microspheresD-Ala2-glucagon-like peptide-1 PLGA formulationD-Ala-2-glucagon-like peptide-1 PLGA formulationD-Ala 2-glucagon-like peptide-1 PLGA formulation[D-Ala2]GLP-1-PLGA-COOH
02
Targets
Beyond the preview
Go deeper on d-ala2-glp-1-plga-cooh.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on d-ala2-glp-1-plga-cooh.